A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

April 15, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Asthma, BronchialLung Diseases, ObstructiveRespiratory Tract DiseasesBronchial Diseases

Interventions

DRUG

PF-00610355

100 mcg, QD, dry powder inhaler

DRUG

PF - 00610355

600 mcg, QD, dry powder inhaler

OTHER

Placebo

QD, dry powder inhaler

DRUG

PF - 00610355

300 mcg, QD, dry powder inhaler